Literature DB >> 25589830

Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B?

Ji Hoon Kim1, June Sung Lee2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25589830      PMCID: PMC4293558          DOI: 10.3904/kjim.2015.30.1.23

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


× No keyword cloud information.
  11 in total

1.  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

Authors: 
Journal:  J Hepatol       Date:  2012-03-20       Impact factor: 25.083

2.  Chronic hepatitis B: update 2009.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

3.  Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.

Authors:  Florian van Bömmel; Robert A de Man; Heiner Wedemeyer; Katja Deterding; Jörg Petersen; Peter Buggisch; Andreas Erhardt; Dietrich Hüppe; Kerstin Stein; Jörg Trojan; Christoph Sarrazin; Wulf O Böcher; Ulrich Spengler; Hermann E Wasmuth; Jurrien G P Reinders; Bernd Möller; Peter Rhode; Heinz-Hubert Feucht; Bertram Wiedenmann; Thomas Berg
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

4.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Authors:  Patrick Marcellin; Edward Gane; Maria Buti; Nezam Afdhal; William Sievert; Ira M Jacobson; Mary Kay Washington; George Germanidis; John F Flaherty; Raul Aguilar Schall; Jeffrey D Bornstein; Kathryn M Kitrinos; G Mani Subramanian; John G McHutchison; E Jenny Heathcote
Journal:  Lancet       Date:  2012-12-10       Impact factor: 79.321

5.  KASL Clinical Practice Guidelines: Management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2012-06-26

6.  Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.

Authors:  Scott Fung; Peter Kwan; Milotka Fabri; Andrzej Horban; Mijomir Pelemis; Hie-Won Hann; Selim Gurel; Florin A Caruntu; John F Flaherty; Benedetta Massetto; Phillip Dinh; Amoreena Corsa; G Mani Subramanian; John G McHutchison; Petr Husa; Edward Gane
Journal:  Gastroenterology       Date:  2013-12-22       Impact factor: 22.682

7.  Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Authors:  Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.

Authors:  Xiaoping Qi; Shelly Xiong; Huiling Yang; Michael Miller; William E Delaney
Journal:  Antivir Ther       Date:  2007

9.  Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir.

Authors:  Wai-Kay Seto; Kevin Liu; James Fung; Danny Ka-Ho Wong; John Chi-Hang Yuen; Ivan Fan-Ngai Hung; Ching-Lung Lai; Man-Fung Yuen
Journal:  Antivir Ther       Date:  2012-09-06

10.  Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.

Authors:  Hyo Jin Kim; Ju-Yeon Cho; Yu Jin Kim; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo; Joon Hyeok Lee
Journal:  Korean J Intern Med       Date:  2014-12-30       Impact factor: 2.884

View more
  1 in total

1.  The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy.

Authors:  Jeong Han Kim; Sung Hyun Ahn; Soon Young Ko; Won Hyeok Choe; Kyun-Hwan Kim; So Young Kwon
Journal:  Clin Mol Hepatol       Date:  2016-06-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.